Desentum is a research-oriented, clinical-stage biopharmaceutical company that specializes in developing innovative allergy vaccines. With a focus on switching the immune system's response to allergens from hypersensitivity to tolerance, Desentum offers a unique approach to allergen immunotherapy products. By studying the molecular mechanism of hypersensitivity reactions, their team has made groundbreaking discoveries that lead to improved design of immunotherapeutic products for common allergies.

Desentum aims to provide long-term relief for patients suffering from allergic symptoms while reducing the social and economic burden on individuals and society. Founded in 2011, Desentum's story began in Finland, where scientists at the University of Eastern Finland and VTT Technical Research Center made exciting findings about the interaction between allergens and IgE proteins. Working closely with their main R&D collaborators, Desentum has identified promising candidate products and is currently in clinical development.

They also collaborate with other companies and research groups to evaluate the effectiveness of their products. With the increasing prevalence of allergies globally, Desentum's research and development efforts offer hope for a better future in allergy treatment